1024 related articles for article (PubMed ID: 14991453)
1. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
3. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
Engelborghs S
Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
[TBL] [Abstract][Full Text] [Related]
4. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein.
Hampel H; Goernitz A; Buerger K
Brain Res Bull; 2003 Aug; 61(3):243-53. PubMed ID: 12909294
[TBL] [Abstract][Full Text] [Related]
5. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
6. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
7. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
[TBL] [Abstract][Full Text] [Related]
8. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia.
Engelborghs S; Le Bastard N
J Neurol Sci; 2012 Nov; 322(1-2):197-9. PubMed ID: 22947896
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of Alzheimer's disease: the present and the future.
Lehmann S; Delaby C; Touchon J; Hirtz C; Gabelle A
Rev Neurol (Paris); 2013 Oct; 169(10):719-23. PubMed ID: 24021316
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid biomarkers for Alzheimer's disease.
Blennow K; Zetterberg H
J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
[TBL] [Abstract][Full Text] [Related]
12. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria.
Höglund K; Fourier A; Perret-Liaudet A; Zetterberg H; Blennow K; Portelius E
Clin Chim Acta; 2015 Sep; 449():3-8. PubMed ID: 25668231
[TBL] [Abstract][Full Text] [Related]
14. Biological markers of Alzheimer's disease.
de Souza LC; Sarazin M; Teixeira-Júnior AL; Caramelli P; Santos AE; Dubois B
Arq Neuropsiquiatr; 2014 Mar; 72(3):227-31. PubMed ID: 24676441
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
[TBL] [Abstract][Full Text] [Related]
16. Added diagnostic value of CSF biomarkers in differential dementia diagnosis.
Le Bastard N; Martin JJ; Vanmechelen E; Vanderstichele H; De Deyn PP; Engelborghs S
Neurobiol Aging; 2010 Nov; 31(11):1867-76. PubMed ID: 19150153
[TBL] [Abstract][Full Text] [Related]
17. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K
Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877
[TBL] [Abstract][Full Text] [Related]
19. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.
Prvulovic D; Hampel H
Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022
[TBL] [Abstract][Full Text] [Related]
20. The load of amyloid-β oligomers is decreased in the cerebrospinal fluid of Alzheimer's disease patients.
Sancesario GM; Cencioni MT; Esposito Z; Borsellino G; Nuccetelli M; Martorana A; Battistini L; Sorge R; Spalletta G; Ferrazzoli D; Bernardi G; Bernardini S; Sancesario G
J Alzheimers Dis; 2012; 31(4):865-78. PubMed ID: 22717612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
